Total Voting Rights

RNS Number : 1580B
Hutchmed (China) Limited
30 September 2022
 

 

Total Voting Rights

 


Hong Kong, Shanghai, & Florham Park, NJ - Friday, September 30, 2022: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 30, 2022, the issued share capital of HUTCHMED consisted of 864,775,340 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 864,775,340 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For illustrative purposes only, the 864,775,340 ordinary shares would be equivalent to 864,775,340 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 172,955,068 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries


Mark Lee, Senior Vice President

+852   2121   8200

Annie Cheng, Vice President

+1   (973)   567   3786



Media Enquiries

 

Americas  - Brad Miles, Solebury

+1   (917)   570   7340   (Mobile) | bmiles@soleburystrat.com

Europe  - Ben Atwell / Alex Shaw, FTI

+44   20   3727   1030 / +44   7771   913   902   (Mobile) / +44 7779 545 055 (Mobile) | HUTCHMED@fticonsulting.com

Asia  - Zhou Yi, Brunswick

+852   97 83   6894   (Mobile) | HUTCHMED@brunswickgroup.com



Nominated Advisor


Atholl Tweedie / Freddy Crossley,
Panmure Gordon (UK) Limited

+44   (20)   7886   2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDZGZLRLGGZZG
UK 100

Latest directors dealings